Are We Ready to Include Organ-Impaired Patients in Oncology Trials? A Clinical Pharmacology Perspective on Recent Recommendations.

Masters, Joanna C; Wiernik, Peter H

Masters, Joanna C; Wiernik, Peter H.

Affiliation

Masters JC; Public Policy Committee of the American College of Clinical Pharmacology, Ashburn, VA, USA.
Wiernik PH; Oncology Clinical Pharmacology, Pfizer Inc., La Jolla, CA, USA.

J Clin Pharmacol ; 58(6): 701-703, 2018 06.

Article in En | MEDLINE | ID: mdl-29663409

Subject(s)

Clinical Trials as Topic/ethics; Kidney Diseases/physiopathology; Liver Diseases/physiopathology; Medical Oncology/ethics; Neoplasms/therapy; Patient Selection/ethics; Clinical Trials as Topic/methods; Humans; Kidney Diseases/complications; Liver Diseases/complications; Neoplasms/complications; Neoplasms/physiopathology; Pharmacology, Clinical; Risk Assessment

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Clinical Trials as Topic / Patient Selection / Kidney Diseases / Liver Diseases / Medical Oncology / Neoplasms Type of study: Etiology_studies / Guideline / Risk_factors_studies Limits: Humans Language: En Journal: J Clin Pharmacol Year: 2018 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google